Advanced Evolution of Pathogenesis Concepts in Cardiomyopathies

Chia-Jung Li 1,‡, Chien-Sheng Chen 2,3,‡, Giou-Teng Yiang 2,3, Andy Po-Yi Tsai 4,‡, Wan-Ting Liao 5,6,∗ and Meng-Yu Wu 2,3,∗

1 Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan; nigel6761@gmail.com
2 Department of Emergency Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei 231, Taiwan; holeyeye@yahoo.com.tw (C.-S.C.); gtyiang@gmail.com (G.-T.Y.)
3 Department of Emergency Medicine, School of Medicine, Tzu Chi University, Hualien 970, Taiwan
4 Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien 970, Taiwan; tandy@iu.edu
5 Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
6 Chinese Medicine Department, Show Chwan Memorial Hospital, Changhua 500, Taiwan
∗ Correspondence: enolainsky@gmail.com (W.-T.L.); skyshangrila@gmail.com (M.-Y.W.);
Tel.: +886-4-725-6166 (W.-T.L.); +886-2-6628-4272 (M.-Y.W.)
‡ These authors contributed equally to this work.

Received: 7 March 2019; Accepted: 12 April 2019; Published: 16 April 2019

Abstract: Cardiomyopathy is a group of heterogeneous cardiac diseases that impair systolic and diastolic function, and can induce chronic heart failure and sudden cardiac death. Cardiomyopathy is prevalent in the general population, with high morbidity and mortality rates, and contributes to nearly 20% of sudden cardiac deaths in younger individuals. Genetic mutations associated with cardiomyopathy play a key role in disease formation, especially the mutation of sarcomere encoding genes and ATP kinase genes, such as titin, lamin A/C, myosin heavy chain 7, and troponin T1. Pathogenesis of cardiomyopathy occurs by multiple complex steps involving several pathways, including the Ras-Raf-mitogen-activated protein kinase-extracellular signal-activated kinase pathway, G-protein signaling, mechanotransduction pathway, and protein kinase B/phosphoinositide 3-kinase signaling. Excess biomechanical stress induces apoptosis signaling in cardiomyocytes, leading to cell loss, which can induce myocardial fibrosis and remodeling. The clinical features and pathophysiology of cardiomyopathy are discussed. Although several basic and clinical studies have investigated the mechanism of cardiomyopathy, the detailed pathophysiology remains unclear. This review summarizes current concepts and focuses on the molecular mechanisms of cardiomyopathy, especially in the signaling from mutation to clinical phenotype, with the aim of informing the development of therapeutic interventions.

Keywords: cardiomyopathy; genetic mutations; cardiac remodeling; apoptosis; fibrosis

1. Introduction

Cardiomyopathy refers to a group of heterogeneous genetic or idiopathic cardiac diseases that feature myocardial structural and functional abnormalities that occur due to myocyte injuries [1]. The anatomic changes and cell death induce electrical dysfunction contraction abnormalities of the heart, causing arrhythmia and heart failure. The reported etiologies include chronic hypertension, valvular heart disease, and toxin exposure [2]. Ischemic heart diseases and induced myocardial disorders are also included. Genetic mitochondrial dysfunction has been a focus of study [3]. However, clinical and basic studies carried out over a long time have not clarified details of the pathophysiology. Recent studies have focused on the molecular and genetic aspects of cardiomyopathy, including local...
inflammation, reperfusion injury, death, remodeling, and recovery of myocardia, with the goal of informing novel approaches for clinical and prognostic assessments [4,5]. In this review, we summarize the current concepts concerning the cell biology and molecular regulation of cardiomyopathy with the aim of informing the development of therapeutic interventions.

2. Clinical Features of Genetic Cardiomyopathy

The heterogeneous conditions that encompass cardiomyopathy feature myocardial dysfunction with structural and functional abnormalities, and are broadly classified as familial types and non-familial types [6]. Based on structural and functional abnormalities, these types can be further classified into four major categories: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) (Figure 1). In familial types of cardiomyopathy, left ventricular non-compaction (LVNC) is considered an unclassified type. Takotsubo cardiomyopathy and tachycardiomyopathy are two common cardiomyopathies that are classified as non-familial types [7]. The primary causes of the different types of cardiomyopathies are heterogeneous, but they share a final common pathway leading to cardiac dysfunction.

Figure 1. Risk factors of the four major types of cardiomyopathy.

3. DCM

DCM is characterized by the structural dilation of ventricles associated with poor contraction. DCM is the most common cardiomyopathy, with an incidence ranging from 5–8 cases per 100,000 people [8]. Similar to the other three major types of cardiomyopathies, DCM is classified as primary or secondary types. In primary DCM, genetic causes that are independent of age include Titin (TTN), Lamin A/C (LMNA), Myosin heavy chain 7 (MYH7), and Troponin T2 (TNNT2) mutations. The familial DCM accounts for 20–48% of total DCM [9]. Mutations that affect sarcomeric and intrasarcomeric proteins can induce decreased contraction force via calcium signaling in mechanotransduction pathways [10]. Mutation of LMNA, which encodes nuclear lamin A and nuclear lamin C, is important in the pathogenesis of DCM. LMNA-related DCM may present with left ventricular enlargement and poor systolic function, promoting significant conduction system dysfunction and arrhythmias [11,12]. Peters et al. [13] reported 11 genes associated with DCM and ventricular arrhythmias, including LMNA, sodium voltage-gated channel alpha subunit 5 (SCN5A), RNA binding motif protein 20 (RBM20), filamin C (FLNC), and TTN. In these populations, in which the mortality rate can be high, the
implantable cardioverter-defibrillator (ICD) may provide benefit for the primary prevention of sudden cardiac death.

Etiologies reported in secondary DCM include myocarditis, Kawasaki disease, Churg-Strauss syndrome, drug-related toxicity, endocrine disturbance, hypophosphatemia, hypocalcemia, and tachycardiomyopathy [6,14,15]. Dilated cardiomyopathy from ischemic cardiomyopathy is an important etiology. Patients with ischemia-induced DCM may present with left ventricular dysfunction and wall motion hypokinesia. Iskandrian et al. [16] described the assessment of right ventricular function to rule out ischemic cardiomyopathy, based on the knowledge that preserved right ventricular function is a characteristic in ischemia-induced DCM. The detailed mechanism has been investigated. Ischemic events may trigger the accumulation of oxidative stress and promote apoptosis of cardiomyocytes [17]. After percutaneous coronary intervention, the enhanced production of reactive oxygen species from reperfusion injury also causes cell death, which induces cardiac remodeling to form DCM. Early diagnosis and timely intervention of ischemic events are effective to prevent DCM.

Pediatric DCM is a rare disorder, with 0.57 cases per 100,000 person-years reported in the United States [18]. When it occurs, it is serious. Risk factors include gender (0.66 vs 0.47 cases per 100,000 in boys vs. girls, respectively), race (0.98 vs 0.46 cases per 100,000 in blacks vs. whites, respectively), and age (4.40 vs 0.34 cases per 100,000 in infants < 1 year-of-age vs. children, respectively) [18]. Common causes of pediatric DCM are myocarditis (46% of cases) and neuromuscular disease (26% of cases). The clinical outcome is poor, with reported 1-year and 5-year rates of death or heart transplantation of 31% and 46%, respectively [19]. Similar genetic etiologies are suspected in adult and pediatric DCM. However, the medications routinely used in adult DCM are not effective in pediatric patients. Patel et al. [20] reported that pediatric and adult DCM are induced by different pathophysiological conditions and that pediatric DCM does not feature adverse remodeling [20]. The detailed pathophysiology in pediatric DCM is unclear.

Secondary etiologies of cardiomyopathy include infection, autoimmune diseases, drug-related toxicity, endocrinology, nutritional deficiency, and electrolyte imbalance. These can also impair the contraction force and decrease transmission [21]. To compensate for left ventricular (LV) systolic dysfunction, the LV remodeling process produces chamber dilatation to form DCM, due to an inappropriate transcriptional response to biomechanical stress [22,23]. The detailed etiology of DCM is summarized in Table 1.

Clinical symptoms, including orthopenia, dyspnea, or pitting edema, are present in 80% of DCM patients [8]. Other associated symptoms that can appear in advanced DCM cases include abdominal distention, nausea, poor appetite, fatigue, and cachexia. The initial physical examination typically reveals bilateral peripheral pitting edema, tachycardia, engorged jugular vein, and bilateral crackle. The structural and electrical dysfunctions result in abnormal rhythms in an electrocardiogram (ECG), which include non-specific repolarization abnormalities, LV hypertrophy, pathological Q-waves, poor R wave progression, prolonged PR interval (measured from the beginning of the P wave to the beginning of the QRS complex), atrioventricular block, or left bundle branch block. Global LV hypokinesis and dilation are typically detected by echocardiography. In chronic DCM cases, intraventricular thrombi and mitral regurgitation may be detected due to annular dilatation. In one study, 1-year mortality ranged from 25–30% and the 5-year mortality was 50% [24]. LV ejection fraction < 25%, right ventricular (RV) dilation, advanced heart failure class, and poor hemodynamic status at cardiac catheterization are poor prognosis factors related to the development of pulmonary hypertension and mortality [6,21].

Genetic mutations of DCM are important in progressive heart failure, and account for approximately 50% of cases [25]. However, the familial DCM prevalence is difficult to estimate. In a meta-analysis of 23 studies, the prevalence of familial DCM was approximately 23% with a wide range of 2% to 65% [26]. Approximately 40% of cases of familial DCM have an identifiable genetic cause [27]. The mutations involve genes encoding diverse proteins, including those associated with the sarcomere, cytoskeleton, sarcolemma, ion channels, and intercellular junctions. The mutations impair cellular structures and muscle contraction via various pathways. Mutations in sarcomere
proteins are important in RCM, accounting for 30% of the total cases, and include TTN, MYH7, MYH6, TNNT2, tropomyosin 1 (TPM1), and troponin C1 (TNNC1). TTN is the largest human protein and is a component of muscle. Mutation in the TTN gene is key in the potential for disease [28]. TTN mutation impairs associated signaling that is vital to the contraction and relaxation of striated muscle [29,30]. The dysfunction of the titin protein also induces defective transmission of force and transduction [31,32]. Mutations in the MYH7 gene, which encodes β-myosin heavy chain, and TNNT2, which encodes troponin T, also lead to sarcomere unit dysfunction. Troponin T binding to troponin C/F forms the troponin complex, which regulates muscle contraction via calcium sensitivity in the interaction between actin and myosin heavy chain. In DCM, TNNT2 mutation decreases calcium sensitivity in muscle contraction [33].

Table 1. Common etiologies of dilated cardiomyopathy.

| Etiology                  | Features                                                                 |
|---------------------------|--------------------------------------------------------------------------|
| Gene mutation             | LMNA, MYH7, TNNT2, RBM20, TTN, BAG3, SCNSA, FLNC, TNNC1, TNNI3, EYA4, NEBL, NEXN, ANKRD1, CRSF3, DES, SGCD, ILK, PDLIM3, ACTC1, ABCC9, CRYAB, ACTN2, TCAP, LDB3, VCL, LAMA4, MYH6, MYBPC3, MYPN, CTF1, DEM, DNAJC19, DSC2, DSP, EMD, FH12, FKTN, FOXD4, LAMP2, PSEN1, PSEN2, SDHA, SYNE1, SYNE2, TAZ, TCAP, TMPO, TPM1, DMD |
| Neuromuscular diseases     | Duchenne muscular dystrophy, Becker muscular dystrophy (Mutation in dystrophin gene) |
| Syndromeic diseases       | Mitochondrial dysfunction, Tafazzin                                       |
| Infection                 | Virus (parvovirus B19, HPV6, HIV), bacteria, Fungus, parasite             |
| Autoimmune diseases       | Polymyositis/dermatomyositis, Chuang-Strauss syndrome, Wegener’ s granulomatosis, Systemic lupus erythematosus, Sarcoidosis, Giant cell myocarditis |
| Drug and toxicity         | Ethanol, Cocaine, Amphetamine, Iron overload, Antineoplastic drugs (paclitaxel, hypomethylating agents, monoclonal antibodies, tyrosine kinase inhibitors), Psychiatric drugs (Clozapine, Olanzapine, Chlorpromazine, Risperidone, Lithium, Methylphenidate, Tricyclic antidepressants, Phenothiazines) |
| Endocrinology             | Hypothyroidism, Hyperthyroidism, Cushing’s disease, Addison disease, Pheochromocytoma, Stress, Diabetes mellitus |
| Nutritional deficiency    | Thiamine, Zinc, Copper, Selenium                                           |
| Electrolyte imbalance     | Hypocalcemia, Hypophosphatemia                                             |

LMNA: Lamin A/C; MYH7: Myosin heavy chain 7; TNNT2: Troponin T2; TTN: Titin; MYH6: Myosin heavy chain 6; DSP: desmoplakin; RBM20: RNA Binding Motif Protein 20; BAG3: BCL2 associated athanogene 3; SCNSA: Sodium voltage-gated channel alpha subunit 5; FLNC: Filamin C; TNNC1: Troponin C1; PLN: Phospholamban; EYA4: EYA transcriptional coactivator and photophosphate 4; TNNT2: Troponin I3; TPM1: Troponymosin 1; NEBL: Nebeulate; NEXN: Nexilin f-actin binding protein; ANKRD1: ankyrin repeat domain 1; CRSF3: Cysteine and glycine rich protein 3; DES: Desmin; SGCD: Sarcosinyl delta; ILK: Integrin linked kinase; PDLIM3: PDZ and LIM domain 3; ACTC1: Actin; ABCC9: ATP binding cassette subfamily C member 9; CRYAB: Crystallin alpha B; ACTN2: Actinin alpha 2; TCAP: Titin-Cap; LDB3: LIM domain binding 3; VCL: Vinculin; LAMA4: Laminin subunit alpha 4; MYBPC3: Myosin binding protein C3; MYPN: Myopalladin; CTF1: Cardiotrophin 1; DNAJC19: DnaJ heat shock protein family C4; CTD2: Desmocollin 2; EMD: Emerin; FH12: Four and a half LIM domains 2; FKTN: Fukutin; FOXD4: Forkhead box D4; LAMP2: Sialoglycoprotein type B2; PSEN1: Presenilin 1; PSEN2: Presenilin 2; SDHA: Succinyl-CoA:3-hydroxacylCoA thiolase; SYNE2: Spectrin repeat containing nuclear envelope protein 1; TAZ: Tafazzin; HNF6: Human pancreatic beta cell nuclear protein 6; HIV: Human immunodeficiency virus.

4. HCM

HCM is a genetically determined cardiomyopathy characterized by nondilated LV hypertrophy (LVH) [34]. Epidemiology studies have indicated a prevalence of HCM of one case per 500 people [35,36]. The primary cause of HCM are mutations in genes encoding cardiac sarcomeric proteins [37] and AMP kinase, such as TTN, MYH7, MYH6, TNNT2, TNNI3, TPM1, MYBPC3, TNNC1, MYH7, and ACTC1. Mutation of the MYBPC3 gene, which encodes myosin binding protein C, is reportedly associated with HCM formation. In a transgenic mouse model with mutated MYBPC3, sarcomere dysfunction in the heart was evident and HCM formation was promoted [38,39]. The mutations decrease ATP production and regulate contraction force [40–42]. In HCM, these sarcomeric or adenosine triphosphate (ATP) kinase protein mutations may induce increased contraction force via calcium signaling in mechanotransduction pathways and decreased ATP production, leading
to LV diastolic dysfunction [43–45]. Several mechanisms associated with pathogenesis include mechanotransduction, Ras-Raf-mitogen-activated protein kinase (MEK)-extracellular signal-activated kinase (ERK) pathway, protein kinase C (PKC) signaling, mothers against decapentaplegic homolog (SMAD), and mitogen-activated protein kinase (MAPK) pathways. These also promote HCM formation [4,46].

Secondary etiologies include hypertension, obesity, aortic stenosis, athletic training, and deposition of amyloid [47,48]. In genetic HCM, two major mutations in the MYH7 and MYBPC3 genes account for approximately 80% of the total cases [49,50]. The two genes are involved in the induction of different signaling pathways associated with the progression of HCM. The MYH7 gene encodes the myosin heavy chain in the sarcomere thick filament proteins, which hydrolyze ATP to produce the force required for muscle contraction. Myosin typically consists of a globular head domain and coiled-coil rod domain. The globular head domain protrudes into the interfilament space to interact with thin filaments [51]. The mutation of MYH7 involves amino acid substitutions in important residues and domains, especially in the transmission of force [52]. The result is a dysfunction that leads to HCM. This scenario was confirmed in a transgenic rabbit model featuring a mutated MYH7 R400Q gene and in Maine Coon Cats [53,54]. The mutation of the MYBPC3 gene, which encodes cardiac myosin binding protein-C (cMyBP-C), usually results in the absence of the protein. In HCM, MYBPC3 mutations encode pathological truncated proteins. These protein products are not found in HCM tissue [55]. The protein levels in symptomatic heterozygous HCM carriers are low. The results indicated that pathological HCM may be caused by the haploinsufficiency of MYBPC3 mutations [56]. Confirmation of the mechanism was provided by the demonstration of the reduced cMyBP-C level in human symptomatic heterozygous carriers of MYBPC3 mutations compared to normal heart tissue [57]. The mutation impairs the binding sites of myosin and titin via the carboxyl-terminus of cMybp-C, leading to cMyBP-C incorporation in the sarcomere [50,58,59]. cMyBP-C typically consists of eight immunoglobulin domains and three fibronectin domains. It protrudes into the interfilament space and interacts with actin via phosphorylation to regulate cross-bridge cycling [60–64]. In HCM, the mutation of cMyBP-C produces aberrant localization in sarcomeres, which induces increased tension Ca$^{2+}$ sensitivity and decreases contraction power output [38,39].

Based on recent reports, “sarcomere-positive” mutation individuals vary from approximately 25% to 65% [65–68]. Approximately 50% of HCM patients are not hosts of sarcomeric gene mutations. The mutations in genes encoding calcium handling proteins are another subclass of genetic etiologies. Several mutations in genes encoding calcium handling proteins have been investigated. They include TNNC1 (which encodes cardiac troponin C), PLN (which encodes phospholamban), and JPH2 (which encodes junctophilin 2) [69–71]. Other mutations in calcium handling proteins, such as RYR2 (which encodes ryanodine receptor 2), CASQ2 (which encodes calsequestrin 2), CALR3 (which encodes calreticulin 3), and SRI (which encodes sorcin), have varying degrees of associations to the HCM [48,72].

Biomechanical stress, cytokines, and other growth factors may trigger the Ras-Raf-MEK-ERK, PKC signaling, SMAD, and MAPK pathways, which activate nuclear transcription factors. The resulting cardiac remodeling via cell proliferation and differentiation leads to HCM [7]. ECG reveals typical LVH and other associated findings, such as large QRS complex, Q-waves, and frequent T-wave inversion. The doppler echocardiogram is a common tool to assess HCM. The obstruction of LV outflow tract with a gradient >30 mmHg is reported in approximately 25% of HCM patients [73,74]. Other findings in HCM include normal or reduced LV volume, diastolic dysfunction, and increased systolic pressure gradients. Progressive HCM may induce cardiovascular events, including sudden death due to arrhythmia, chronic heart failure, and atrial fibrillation with stroke. In advanced HCM, the placement of an ICD is an important means of preventing sudden death caused by arrhythmia. Other effective treatments for symptomatic HCM include surgical myectomy and alcohol septal ablation, controlling the symptoms of heart failure, and progressive atrial fibrillation. In end-stage HCM, heart transplantation is necessary.
5. RCM

RCM is a lethal cardiomyopathy characterized by LV diastolic dysfunction without LV dilation. The etiology of RCM includes genetic initiators, skeletal muscle myopathies, local scarring, infection, and deposition of amyloid [75]. In familial RCM, sarcomeric and cytoskeletal gene mutations commonly reported in RCM include TNNT3, TNNT2, MYH7, DES, MYBPC3, LMNA, FLNC, and LAMP2. These mutations are involved in the progression of RCM due to impaired actin-myosin interactions and cardiac contractility [76–78]. The sarcomere typically consists of two major components, actin and myosin, which comprise the thin and thick filament. The filaments regulate muscle contraction and force development in a Ca^{2+}-dependent manner via the troponin complex. Cardiac troponin consists of three subunits and is located in thin filaments. The protein regulates muscle contraction in a Ca^{2+} sensitive manner [79]. The TNNT2 and TNNI3 genes encode cardiac troponin I and T, respectively, which respectively function as a Ca^{2+} inhibitory subunit and Ca^{2+}-binding signaling transmitter [80]. During electrical depolarization, the calcium channel allows Ca^{2+} influx and binding to cardiac tropinin, which activates the troponin complex, inhibits cTnl, and leads to an interaction between actin and myosin. Nine recently-reported mutations in genes encoding cTnl markedly increase myofilament Ca^{2+} sensitivity [81,82]. The MYH7 and MYBPC3 gene mutations have been identified in RCM and HCM. The mutations in the actin-myosin contractile apparatus induce diastolic dysfunction and promote the progression of RCM. The list of RCM-associated mutations is often similar to those genes in HCM and DCM. However, compared to HCM and DCM, the RCM has a low rate of detection (<30%) [77,83]. In DCM, a genetic study reported a 30–40% rate of genetic mutation in familial DCM population [84]. In HCM, 50–60% of people with a family history of HCM will have a mutation identified in one of the sarcomeric genes [36,85].

Mutations in sarcomeric protein disrupt the mechanical property and the ability of muscle to contract and relax via calcium signaling in mechanotransduction pathways [86,87]. In non-familial RCM, the deposition of amyloid, scleroderma, endomyocardial fibrosis, hyper eosinophilic syndrome, and drug toxicity may promote local inflammation and biomechanical stress to trigger the pathways of Wnt signaling, protein kinase B/phosphoinositide 3-kinase (AKT/PI3K) signaling, Ras-Raf-MEK-ERK, PKC signaling, SMAD, and MAPK [88,89]. These signaling pathways involve cardiac remodeling and trigger ventricular wall stiffness, cardiomyocytes apoptosis, myofibrillar disarray, and fibrosis. Typical symptoms include pulmonary congestion, dyspnea on exertion, and syncope. Stiffness of the myocardium leads to increased ventricular pressure and typically normal ventricular dimensions, dilated atria due to systemic venous congestion, diastolic dysfunction, and normal systolic function in echocardiography [78,90]. Symptomatic RCM can be effectively treated by restricting water and salt restriction with diuretics and aldosterone antagonists. In severe cases of RCM, chelation therapy, phlebotomy, placement of an (ICD), or cardiac transplantation is considered.

6. ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy)

ARVC (arrhythmogenic RV dysplasia) is characterized by structural change in the myocardium of RV inflow, outflow tract, or apex with fibrofatty tissue. ARVC leads to regional wall motion abnormalities, and global or RV dilation. The reported prevalence is 1 in 5000 individuals [91]. In ARVC, genetic mutations account for approximately 40–60% of cases. The mutations include genes encoding junction plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein (DSG), and desmocollin (DSC). Clinical genetic studies have revealed that 30% of cases of ARVC are caused by genetic mutation. The autosomal dominant form that is common in ARVC includes five major genes: DSP, PKP2, DSG2, DSC2, and TMEM43. The autosomal recessive form of ARVC is less common, and involves mutations of the plakoglobin and desmoplakin genes (Naxos disease and Carvajal syndrome) [92–94]. Desmosomes consist of five proteins: JUP, PKP2, DSP, DSG2, and DSC2. Desmosomes are responsible for cell adhesion and interaction between myocardial cells [95]. In desmosomes, desmoglein and plakoglobin are located in the transmembrane surface and interact with desmocolin and plakoglobin [96]. Desmosomes are important for electrical conduction and mechanical
contraction in myocytes [97]. In ARVC, mutations that affect desmosomes lead to decreased force and mechanical stress between cells due to myocyte detachment and cell death [98]. Myocyte death promotes local inflammation and fibrofatty change. The structural change induces heart remodeling by replacement of injured myocytes [99]. The scar tissue also disrupts electrical transduction and promotes the progression of ARVC. In addition, mutation of the ryanodine receptor 2 (RYR2) gene plays an important role in ARVC [100]. Mutated RYR2 impairs calcium release from the sarcoplasmic reticulum. The imbalance of excitation–contraction coupling due to impaired intracellular calcium content may induce arrhythmias. Intracellular calcium content change may trigger cellular death and cause cardiac fibrosis [92].

The mutations can induce arrhythmia and pathological structural change [93,101–103]. Cardiac-specific mutations of the desmosomal protein desmoplakin lead to nuclear localization of the desmosomal protein plakoglobin and also decrease the activation of Wnt/beta-catenin (CTNNB1) signaling mediated by T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factors [104]. These signaling disturbances trigger the expression of adipogenic and fibrogenic genes, and promote ventricular dilation and fibrofatty infiltration. Prolonged ventricular fibrosis and cardiomyocyte apoptosis in cardiac remodeling can cause arrhythmia and pathological structural change that results in RV cardiomyopathy. Secondary etiologies can be triggered by the inflammatory response and lead to cardiac remodeling. Arrhythmia may be induced during athletic activity by the exercise-induced release of catecholamine, leading to sudden cardiac arrest. Other typical symptoms include palpitations, syncope, atypical chest pain, and dyspnea [105]. In ECG analysis, sustained or non-sustained monomorphic VT and left bundle branch block are common in ARVC cases [106]. Prevention of sudden cardiac death is important in ARVC patients. In advanced ARVC cases, placement of an ICD is necessary.

7. LVNC

LVNC was an unclassified cardiomyopathy until it was proposed as a familial type in 2008 [107]. Two features in LVNC have been reported. One is the prominent trabeculae and deep intertrabecular recesses in the LV, which form non-compacted and compacted layers of myocardium. The other feature is the continuity of the LV cavity with deep intratrabecular recesses [108]. Several hypotheses proposed to explain the pathophysiology include intrauterine arrest leading to congenital malformation of the heart [109]. Cardiac remodeling can lead to prominent trabeculations during adult life in response to the LV loading [110]. Several gene mutations have been investigated in LVNC (Table 2). The inheritance of LVNC can be common in X-linked recessive or autosomal dominant conditions, especially in Barth syndrome, resulting from mutation of the TAZ gene. Autosomal dominant LVNC may present with differing severities in family members, and can include septal defects and Ebstein’s anomaly [111–114]. The genetic causes are heterogeneous, but the final common signaling is similar to other cardiomyopathies [108]. A large group of sarcomere encoding gene mutations, including LDB3, MYH7, ACTC1, TNNT2, MYBPC3, TPM1, and TNNI3, have been noted in up to 20% of LVNC cases, especially in MYH7 and MYBPC3 mutations, with rates of up to 13% and 8% [110,115,116]. TAZ and LMNA mutations in LVNC impair calcium handling [115]. In addition, mitochondrial genome mutations and chromosomal abnormalities have also been reported in LVNC [117,118]. Several signaling pathways that have been implicated include the Wnt/planar cell polarity (PCP) and Notch signaling pathways. In the NOTCH pathway, FK506-binding protein 1A (FKBP1A), which is a novel negative modulator of activated NOTCH1 that also interacts with several intracellular protein complexes, is important in regulating cardiomyocyte proliferation [119,120]. In vitro, deficient FKBP1A expression results in ventricular hypertrabeculation and non-compaction of the ventricular wall [121]. The Wnt/PCP pathway regulates embryonic patterning and organogenesis. In the Wnt/PCP signaling pathway, Wnt binding with the frizzled receptor activates phospholipase C (PLC) to promote downstream protein activation, including inositol 1,4,5-triphosphate (IP3), 1,2 diacylglycerol (DAG), and PKC, which in turn trigger the release of calcium ions into the cytoplasm. The activated PKC can also interact with other signaling pathways, such as MAPK signaling pathways. Wnt/PCP regulates
cardiomyocyte polarity, myofibrillogenesis, and development of ventricular non-compaction via a large number of PCP effectors, which include disheveled-associated activator of morphogenesis 1 (DAAM1). In vitro, mutations in Wnt/PCP signaling key components, such as VANGL planar cell polarity protein 2 (VANGL2), scribble planar cell polarity protein (SCRIB), disheveled, and disheveled associated activator of morphogenesis 1 (DAAM1), have been related to the development of ventricular non-compaction [122–126].

8. Genetic Mutations in Cardiomyopathy

Genetic mutations in cardiomyopathy may lead to progressive heart failure. In children and young adults, genetic mutation is a major indication for early heart transplantation or ICD insertion [127]. Several gene mutations are valuable for timely screening in heart failure patients and for prenatal testing [16,128]. The identification of these mutations can be critical in preventing morbidity and mortality, alerting patients and their families, and for population-based studies. Understanding the mutations that are important in cardiomyopathy is essential in personalizing therapy [129]. The identified gene mutations in the five major cardiomyopathies are listed in Table 2.

| Cardiomyopathy | Gene Mutation |
|----------------|---------------|
| Dilated cardiomyopathy | LMNA, MYH7, TNN2, RBM20, TTN, BAG3, SCN5A, FLNC, TPM1, PLN, TNN1, EYA4, NEB, NEXN, ANKRD1, CSR3, DES, SGCD, ILK, PDLIM3, ACTC1, ABC9, CRYAB, ACTN2, TCAP, LDB3, VCL, LAMAA4, MYH6, MYBPC3, MYPN, CTF1, DEM, DNAJC19, DSC2, DSP, EMD, FH2, FKTN, FOXD4, LAMP2, PSEN1, PSEN2, SDHA, SYNE1, SYNE2, TAZ, TCAP, TMPO |
| Hypertrophic cardiomyopathy | TTN, MYH7, MYH6, MYL2, MYL3, MYBPC3, MYLK2, TNN2, TNN3, TPM1, ACTC, TNNC1, LDB3, CSR3, TCAP, VCL, ACTN2, MYOZ2, NEXN, JPH2, PLN, ANKRD1, CAV3, COX15, CRYAB, GLA, LAMP2, PRKAG2 |
| Restrictive cardiomyopathy | TTN3, TTN2, TPN1, MYH7, DES, MYBPC3, LMNA, FLNC, LAMP2 |
| Arrhythmic right ventricular cardiomyopathy | DSP, PKP2, DSG2, DSC2, JUP, TMEM43, CTNNA3, DES, LMNA, PLN, RYR2, TGFβ3, TTN, SCN5A, ARVC3, ARVC6, |
| Left ventricular non-compaction cardiomyopathy | LDB3, DTNA, TAZ, LMNA, NKX2-5, MYH7, ACTC, TNN2, TNN13, MYBPC3, SCN5A, SNTA1, PRDM16, TPM1, NSD1, RP56K3, PMP22, CASQ, MYH6 |

LMNA: Lamin A/C; MYH7: Myosin heavy chain 7; TTN2: Troponin T2; TTN: Titin; TCAP: TTN-Cap; MYH6: Myosin heavy chain 6; DSC: desmocollin; DSP: desmoplakin; PKP2: plakophilin-2; DSG2: desmoglein; JUP: junction plakoglobin; RYR2: ryanodine receptor 2; ARVC: arrhythmogenic right ventricular cardiomyopathy; CASQ2: which encodes calsequestrin 2; BCL2: B-cell lymphoma 2; CFLG3: CFLG3 associated activator of morphogenesis 1; FLNC: Filamin C; TPM1: Tropomyosin 1; PLN: Phospholamban; TNNC1: Troponin C1; TNNT3: Troponin T3; EYA4: EYA transcriptional coactivator and phosphatase 4; NEB: Nebulette; NEXN: Nexilin f-actin binding protein; ANKRD1: ankyrin repeat domain 1; CSR3: Cysteine and glycine rich protein 3; DES: Desmin; SGCD: Sarcoglycan delta; ILK: Integrin linked kinase; PDLIM3: PDZ and LZM domain 3; ACTC1: Actin, ABCG9: ATP binding cassette subfamily C member 9; CRYAB: Crystallin alpha B; ACTN2: Actin alpha 2; LDB3: LIM domain binding 3; VCL: Vinculin; LMAMA4: Lamin subunit alpha 4; MYBPC3: Myosin binding protein C3; MYPN: Myopalladin; CTF1: Cardiotrophin 1; DNAJC19: DnaJ heat shock protein family (Hsp40) member C19; EMD: Emerin; FH2: Four and a half LIM domains 2; FKTN: Fukutin; FOXD4: Forkhead box D4; LAMP2: Lysosomal associated membrane protein 2; PSEN2: Presenilin 2; SDHA: Succinate dehydrogenase complex flavoprotein subunit A; SYNE1: Spectrin repeat containing nuclear envelope protein 1; SYNE2: Spectrin repeat containing nuclear envelope protein 2; TAZ: Tafazzin; TMPO: Thymopoietin; MYL2: Myosin Light Chain 2; MYL3: Myosin Light Chain 2; MYL2: Myosin light chain kinase 2; LDB3: LIM domain binding 3; MYOZ2: Myozin 2; JPH2: Junctophilin 2; CAV3: Caveolin 3; COX15: Crystallin alpha B; PLA2G4G: Protein kinase AMP-activated non-catalytic subunit gamma 2; TPM1: Vitamin B6 transporter TPM1; TMEM43: transmembrane protein 43; CTNNA3: Catenin alpha 3; TGFβ3: Transforming growth factor beta 3; DTNA: Dystrophia myotonica; NKX2-5: NKX2-5; NK2: Homeobox 5; TNN13: Troponin I3; SNTA1: Syntrophin alpha 1; PRDM16: PR/SET domain 16; NSD1: Nuclear receptor binding SET domain protein 1; RP56K3: Ribosomal protein S6 kinase A3; PMP22: Peripheral myelin protein 2.

9. Pathophysiology of Cardiomyopathy

Cardiomyopathy features multiple steps and usually involves several pathways, which include cardiac hypertrophy, G-protein pathway, fibrosis, apoptosis, and AKT signaling. Infection, metabolic disease, presence of toxins, or deposition of amyloid can lead to myocardial injury and remodeling
Specific mutations of these genes impair the muscular contraction mechanism due to the sensitivity of ion channels, calcium regulation, and the transmission of mechanical force. To understand the detailed mechanisms, many studies have focused on the genetic background of cardiomyopathy and have attempted to understand the detailed signaling pathways within the enormous complexity of cardiomyopathy. Several major pathways of cardiomyopathy have been reported and investigated. In the following subsections, we discuss the major signaling pathways that play an important role in cardiomyopathy.

9.1. Ras-Raf-MEK-ERK Pathway in Cardiac Myocyte Hypertrophy

A variety of pathologic or physiological stress stimuli can impair contractility and $\text{Ca}^{2+}$ sensitivity. The affected cardiomyocytes adapt to the increased demands for cardiac work. The increased muscle mass and functional demand of the cardiomyocytes results in the increased thickness of the ventricular walls. This reduces the ventricular volume, which leads to decreased cardiac output. In advanced cases, the poor cardiac output may promote acute heart failure. At the cellular level, the genetic mutation and environment stresses from infection, toxin exposure, autoimmune response, or endocrine imbalance induce several signaling pathways to promote hypertrophy of cardiac myocytes and augmented contractile capacity. As an early response to hypertrophy stress, cell cycle regulation is activated to increase proliferation and inhibit apoptosis of myocytes [130]. The Ras-Raf-MEK-ERK pathway plays a central role in cardiac hypertrophy. The pathway can be activated by several neurohumoral factors, such as cytokines, growth factors, and mechanical stress. Interleukin (IL)-1$\beta$ promotes the Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling pathway and regulates Ras to activate the Ras-Raf-MEK-ERK pathway. In addition, cytokines also activate downstream gp130 pathways to inhibit apoptotic pathways [131]. Growth factors from cardiac myocytes and non-myocytes, such as fibroblast growth factor, transforming growth factor-beta (TGF-$\beta$), insulin-like growth factor, and platelet-derived growth factor, induce cardiomyocyte hypertrophy [132,133]. These growth factors bind to tyrosine kinases to activate Ras. The activation of the Ras/Raf-MEK-ERK pathway promotes cell proliferation and differentiation, leading to cardiac hypertrophy [134]. Gelb et al. [135–137] reported that Ras-Raf-MEK-ERK pathway is a key signaling for cardiomyopathy. The authors described functional $\text{RAF1}$ mutation rates of up to 9% in South Indian, North Indian, and Japanese populations in childhood-onset DCM cases. The $\text{RAF1}$ mutation results in ERK activation in a BRAF-dependent manner to induce heart failure. In addition, the Ras-Raf-MEK-ERK pathway also plays an important role in Noonan syndrome, a developmental disorder with cardiac dysfunction, short stature, and facial dysmorphia. Pandit et al. [138] reported that missense mutations in $\text{RAF1}$ impair the activity of Ras-Raf-MEK-ERK pathway via 14-3-3 binding. The authors described that most (95%) $\text{RAF1}$ mutation cases present with hypertrophic cardiomyopathy (HCM). Thus, $\text{RAF1}$ mutations increase ERK activation and implicate hyperactivation of Ras signaling in HCM.

9.2. G-Protein Signaling in Cardiomyopathy

In response to pathologic or physiological stress stimuli, cardiomyocytes or non-myocytes can release several factors to adapt to the microenvironment. These factors include catecholamines, angiotensin II, and endothelin 1. Their release activates G-protein–coupled receptor signaling. G-proteins consist of $\alpha$, $\beta$, and $\gamma$ subunits. The $\alpha$ subunit converts guanosine-5’-triphosphate (GTP) to guanosine-5’-diphosphate (GDP) and dissociates the $G_{\beta\gamma}$ subunits to activate other downstream signaling [139,140]. The $G_{a}$ subunits interact with enzymes, including adenylyl cyclase and phospholipase C$\beta$ (PLC$\beta$), which mediate ion channel activity. The $G_{\beta\gamma}$ subunits activate several signaling pathways, such as apoptosis and ion channel activation. The G-protein subunits activate downstream signaling cascades and interact with other signaling pathways, such as the Ras-Raf-MEK-ERK, PKC, or SMAD pathway, which promote cardiomyocyte adaptation by hypertrophy and cardiac remodeling. In addition, when the cardiac contractility is reduced, the release of Endothelin 1 (EDN1) and angiotensin II (Ang II) activation of G-protein–coupled receptor signaling also regulates
contractile adaptation by increasing the release of calcium [141]. The Ras-Raf-MEK-ERK pathway is activated, which triggers downstream signaling, including extracellular signal-regulated kinases (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK) signaling, to mediate cardiac growth and remodeling in biomechanical stress. The activation of ERK1/2 via G-protein-coupled receptors can mediate adaptive and maladaptive cardiomyocyte proliferation (Figure 2) [142,143]. In diabetic cardiomyopathy, ERK1/2 signaling was observed in diabetic rat hearts 1 week after the induction of diabetes, which inhibited the overexpression of the antioxidant metallothionein [144].

9.3. Mechanotransduction Pathways

In cardiomyocytes, several proteins participate as key mechanosensors and mechanotransducers in the mechanotransduction pathway. They regulate the response to mechanical load and cellular stress by activating structural change, signaling transduction, and functional remodeling [145]. These complex protein networks interact with the sarcomere and the extracellular matrix (ECM). This mechanotransduction apparatus transfers mechanical stress from the actin–myosin complex to the sarcolemma through the sarcomere, Z-disc, and cellular cytoskeleton [146]. The components of the costamere complex connect the sarcomere and the ECM via integrins. Activation triggered by biomechanical stress and intracellular signaling can alter the contractile properties and regulate the membrane distortion via the PI3K pathway. TTN and muscle LIM protein (MLP) are two key molecular motors for force transmission and sensation within the sarcomere [147]. The detailed mechanism of TTN-directed mechanotransduction signaling was investigated in recent cardiomyopathy studies. TTN spans from the Z-disc to the M-line in sarcomeres. The protein regulates passive stiffness and functions as a signal transducer in mechanical stress overload [148]. MLP binds to α-actinin in the Z-disc. MLP is composed of two LIM domains as a mechanosensor that can activate downstream signaling. The concept of a MLP/TTN-Cap (TCAP)/TTN complex has been proposed and studied. A defect of the MLP/TCAP/TTN complex may lead to the development of cardiomyopathy and heart failure [149]. In vivo, MLP knockout mice developed a severe dilated cardiomyopathy phenotype with hypertrophy and heart failure after birth [150]. Other in vivo analyses identified a human MLP mutation (W4R) in a dilated cardiomyopathy-associated polymorphism. The mutation led to a defect in Tcap interaction/localization, which abolished binding of TCAP to MLP [150,151]. The result was confirmed in an MLPW4RW4R knock-in mouse model [152]. TTN contains a serine/threonine protein kinase domain (TK) at the M-band. The domain interacts with autophagosomal receptor protein complexes, including neighbor of BRCA1 (NBR1), p62 (SQSTM1), and muscle-specific RING finger-2 (MURF2) [153]. The domain also mediates autoinhibition mechanisms, including blocking of the ATP binding site via C-terminal regulatory tail and inhibiting the catalytic base via tyrosine-170. A recent analysis demonstrated that the mutation of the TTN kinase W260R (p.Trp34072Arg) can lead to early-onset cardiomyopathy and loss of the interaction with NBR1 [154]. These data support the important role of TK in cardiac muscle function and indicate that a defective TK may cause the development of myopathies.

9.4. AKT/PI3K Signaling in Cardiomyopathy

The AKT/PI3K signaling pathway triggers several intracellular and extracellular signals that mediate diverse cellular biology events, such as cell metabolism, growth, proliferation, survival, and angiogenesis [155,156]. The pathway is also important in cardiac adaptation that occurs due to the regulation of protein synthesis, apoptosis, and metabolism [157]. Biomechanical stress and molecular regulators, such as growth factors and cytokines, activate cell membrane receptors to trigger the activation of PI3K and transformation. PI3K phosphorylates the AKT protein by activating phosphatidylinositol 4,5-bisphosphate, phosphatidylinositol 3,4,5-trisphosphate, and phosphoinositide-dependent kinase 1. Finally, AKT inactivates the tuberous sclerosis complex, triggering downstream mechanistic target of rapamycin (mTOR) complex 1 signaling [158]. Chronic activation of the PI3K/AKT pathway occurs in cardiomyopathy. In vitro, the chronic activation of Akt1
gene expression in mice can induce adaptive cardiac hypertrophy and dilated cardiomyopathy [159]. In the acute phase, the AKT pathway can also induce cardiac angiogenesis as an adaptation to adapt cardiac stress by the induction of myocardial expression of vascular endothelial growth factor (VEGF). However, VEGF expression is decreased in the chronic phase and during pathological remodeling. In addition, mTOR also contributes to angiogenesis via the VEGF pathway and increases angiopoietin-2 by triggering the hypoxia inducible factor-1α oxygen-sensing protein (Figure 2) [159–162]. These signals promote angiogenesis during physiological cardiac hypertrophy. The overexpression of activated glycogen synthase kinase 3 (GSK-3), an AKT signaling downstream protein, negatively regulates cardiomyocyte size, reduces heart size, and decreases hypertrophy in response to pathological stimuli [163–165]. In hypertensive cardiomyopathy, GSK-3 is inactivated to reflect the downstream alterations of the AKT signaling cascade [166,167].

10. Apoptosis Signaling in Cardiomyopathy and Heart Failure

Apoptosis signaling in ischemic and other types of cardiomyopathies contributes to cardiac remodeling and heart failure [17,168]. Cardiomyocytes are terminally differentiated via apoptosis. Several signaling pathways mediate the extrinsic and intrinsic apoptotic pathways, including AKT and adrenergic stimulation [169,170]. The persistent activation of adrenergic signaling and release of cytochrome c are significantly associated with apoptosis and fibrosis [171–173]. Apoptosis signaling increases the accumulation of reactive oxygen species in cardiomyocytes, affects cardiac function, and impairs systolic and diastolic functions. Studies of the extrinsic and intrinsic apoptotic pathways in cardiomyopathy have revealed that biomechanical stress overload secondary to aortic banding activates the Bcl-2 family, in turn triggering the apoptosis cascade [174,175]. Intrinsic signaling is activated by binding to BCL-2 and BCL-xL to release BAX and BAK, which leads to the loss of mitochondrial outer membrane potential, causes the release of cytochrome c, and finally promotes caspase-9/3 for apoptosis [176]. The extrinsic pathway is activated by death receptors, including Fas, tumor necrosis factor receptor and death receptors to initiate the caspase cascade [177]. Caspase-8 is activated by FAS-associated death domain, which preludes apoptosis [178]. The cleavage of Bid provides a means of cross-talk between the two apoptotic pathways [179]. In HCM and DCM, the apoptotic pathway is activated via caspase signaling (Figure 2) [180,181]. In heart failure, up-regulation of TNF-induced signaling via Fas receptors is commonly observed [182,183]. Heart biopsies in cardiomyopathy patients have revealed common cell loss reflecting the tight regulation of apoptosis for stress adaptation [184]. The increased expression of caspase-3 with a high cardiomyocyte apoptotic index has been described in hypertensive patients with chronic heart failure, indicating that apoptosis signaling is increased [185]. Persistent apoptosis in cardiomyocytes along with reduced numbers of cardiomyocytes may promote the loss of contractile mass and trigger cardiac remodeling and ventricular arrhythmias in cardiomyopathy.

11. Myocardial Fibrosis and Remodeling

During chronic biomechanical stress and as growth factors accumulate, cardiac remodeling can result from interstitial and perivascular fibrosis. This can lead to pathological structural change in the ventricular chambers. In cardiomyopathy patients, the increased stiffness of ventricular walls significantly impairs diastolic function. The interstitial alteration occurs through stimulation of fibroblasts, which alters the collagen framework in the myocardium. After cardiomyocyte apoptosis, cardiac fibrosis occurs with deposition of collagen types I and III. This deposition compromises the function of cardiomyocytes. The resulting severe fibrosis disrupts the relaxation and contraction events, promotes stiffening of the myocardium, and induces chronic heart failure in cardiomyopathy. Fibrosis signaling is triggered by several pathways, including the TGF-β, JNK/p38, PI3K/AKT, WNT/β-Catenin, and Ras-Raf-MEK-ERK pathways. TGF-β is a key cytokine that promotes the production of ECM proteins in fibroblasts, endothelial cells, and smooth muscle cells [186–188]. TGF-β involves cardiac remodeling in cardiomyopathy via SMAD-mediated and non-SMAD signaling.
In canonical signaling, TGF-β induces SMAD complex for translocation into the nucleus, promoting the fibrosis process. In non-canonical signaling, TGF-β signaling induces SMAD-independent pathways, including the PI3K/AKT and MAPK pathways, NF-κB, RHO/RAC1, and CDC42. In HCM, TGF-β activates hypertrophic signals by triggering myofibroblast differentiation and promotes matrix deposition. In the pressure-overloaded heart disease, the inhibition of TGF-β may control the severity of cardiac hypertrophy and fibrosis to preserve diastolic dysfunction. In DCM, TGF-β may serve as a key signal in the ischemic heart by regulating inflammatory response for scar formation. TGF-β inhibits the release of inflammatory mediators and promotes myofibroblast differentiation, leading to matrix deposition [187]. In HCM and DCM, the deposition of collagen has been associated with the TGF-β expression level. High TGF-β expression was reported in the myocardium and serum of HCM and DCM patients [189,190]. In cardiomyopathy, TGF-β activates local inflammation to facilitate clearance of apoptotic cardiomyocytes, and promotes the remodeling of fibroblasts and endothelial cells by the secretion of ECM proteins (Figure 2) [191,192]. TGF-β also activates the Ras-Raf-MEK-ERK pathway, leading to ERK translocation and phosphorylation of several transcription factors, such as the gene for activator protein 1 (API), to produce ECM proteins [193]. TGF-β may activate the JNK/p38 pathway via the association of TNF receptor associated factor 6 (TRAF6), leading to the phosphorylation of c-JUN and activation of the API transcription factor. The activation of PI3K/AKT signaling via mTOR has been reported in cardiomyopathy, along with the increased production of collagen I. In addition, this pathway can also induce epithelial-mesenchymal transition, which directly contributes to the production of collagen and development of cardiac fibrosis. The development of excessive fibrosis in patients with cardiomyopathy leads to deficits in cardiac function [194,195]. Although several studies have reported that TGF-β expression involves in DCM and HCM, the detailed mechanisms remain unclear due to lack strong evidence of TGF-β in the remodeled heart [196].

**Figure 2.** Schematic drawing of the details of the signaling pathways of five major cardiomyopathies. Several pathways, including genetic mutation, Ras/Raf/MEK/ERK signaling pathway, G-protein signaling, Wnt/β-catenin signaling pathway, AKT/PI3K Pathway, TGF-β signaling, JNK/p38 pathway,
and apoptosis pathway, are involved in cardiomyopathy to promote angiogenesis, cell growth, apoptosis and fibrosis, leading to ventricular dilation, hypertrophy, or restriction. FGF: Fibroblast growth factor; IGF: Insulin like growth factor; PDGF: Platelet derived growth factor; TGF: transforming growth factor; PKA: Protein kinase A; PI3K: Phosphoinositide 3-kinases; AKT: Protein kinase B; IL: Interleukin; PTEN: Phosphatase and tensin homolog; JAK: Janus kinase; MEKK: Mitogen-activated protein kinase kinase; JNK: c-Jun N-terminal kinase; STAT: Signal transducer and activator of transcription; APC, TNF: Tumor necrosis factor receptor type 1; Fas: Fas cell surface death receptor.

12. Conclusions

Cardiomyopathy is a complex disease that is triggered by several risk factors, including genetic mutation, neuromuscular disease, infection, drugs, and toxicity. There are four major types of cardiomyopathies. Several pathways are activated by biomechanical stress. Other growth factors, such as the Ras/Raf/MEK/ERK signaling pathway, G-protein signaling, Wnt/β-catenin signaling pathway, AKT/PI3K pathway, TGF-β signaling, JNK/MAPK pathway, and the apoptosis pathway, have been implicated in cardiomyopathy. These pathways promote angiogenesis, cell growth, apoptosis, and fibrosis, leading to ventricular dilation, hypertrophy, or restriction. In addition, the PI3K/AKT pathway also induces epithelial-mesenchymal transition, directly contributing to the production of collagen and cardiac fibrosis.

Author Contributions: Conceptualization, C.-S.C., C.-J.L. Writing—Original Draft Preparation, M.-Y.W. and C.-J.L.; Writing—Review and Editing, W.-T.L.; Visualization, G.-T.Y. and A.P.-Y.T. Supervision, M.-Y.W. and C.-J.L.

Funding: This study was funded by grants from Taipei Tzu Chi Hospital (TCRD-TPE-108-5).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Augustine, D.X.; Howard, L. Left Ventricular Hypertrophy in Athletes: Differentiating Physiology From Pathology. *Curr. Treat. Options Cardiovasc. Med.* 2018, 20, 96. [CrossRef]
2. Wu, M.-Y.; Li, C.-J.; Hou, M.-F.; Chu, P.-Y. New Insights into the Role of Inflammation in the Pathogenesis of Atherosclerosis. *Int. J. Mol. Sci.* 2017, 18, 2034. [CrossRef]
3. Fu, Y.; Eisen, H.J. Genetics of Dilated Cardiomyopathy. *Curr. Cardiol. Rep.* 2018, 20, 121. [CrossRef]
4. Ehler, E. Actin-Associated Proteins and Cardiomyopathy-the 'Unknown' Beyond Troponin and Tropomyosin. *Biophys. Rev.* 2018, 10, 1121–1128. [CrossRef] [PubMed]
5. Kraft, T.; Montag, J. Altered Force Generation and Cell-to-Cell Contractile Imbalance in Hypertrophic Cardiomyopathy. *Pflug. Arch.* 2019. [CrossRef] [PubMed]
6. Vikhorev, P.G.; Vikhoreva, N.N. Cardiomyopathies and Related Changes in Contractility of Human Heart Muscle. *Int. J. Mol. Sci.* 2018, 19, 2234. [CrossRef] [PubMed]
7. Cooper, R.M.; Raphael, C.E.; Liebregts, M.; Anavekar, N.S.; Veselka, J. New Developments in Hypertrophic Cardiomyopathy. *Can. J. Cardiol.* 2017, 33, 1254–1265. [CrossRef]
8. Dec, G.W.; Fuster, V. Idiopathic dilated cardiomyopathy. *N. Engl. J. Med.* 1994, 331, 1564–1575. [CrossRef] [PubMed]
9. Taylor, M.R.; Carniel, E.; Mestroni, L. Cardiomyopathy, familial dilated. *Orphanet J. Rare Dis.* 2006, 1, 27. [CrossRef]
10. Wilson, K.; Lucchesi, P.A. Myofilament dysfunction as an emerging mechanism of volume overload heart failure. *Pflug. Arch.* 2014, 466, 1065–1077. [CrossRef] [PubMed]
11. Brayson, D.; Shanahan, C.M. Current insights into LMNA cardiomyopathies: Existing models and missing LINCs. *Nucleus* 2017, 8, 17–33. [CrossRef] [PubMed]
12. Hershberger, R.E.; Morales, A. LMNA-Related Dilated Cardiomyopathy. In *GeneReviews®* (R); Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993.
13. Peters, S.; Kumar, S.; Elliott, P.; Kalman, J.M.; Fatkin, D. Arrhythmic Genotypes in Familial Dilated Cardiomyopathy: Implications for Genetic Testing and Clinical Management. *Heart Lung Circ.* 2019, 28, 31–38. [CrossRef] [PubMed]

14. Selvaraju, V.; Joshi, M.; Suresh, S.; Sanchez, J.A.; Maulik, N.; Maulik, G. Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease—An overview. *Toxicol. Mech. Methods* 2012, 22, 330–335. [CrossRef]

15. Wang, X.; Zabell, A.; Koh, W.; Tang, W.H. Lamin A/C Cardiomyopathies: Current Understanding and Novel Treatment Strategies. *Curr. Treat. Options Cardiovasc. Med.* 2017, 19, 21. [CrossRef]

16. Iskandrian, A.S.; Helfeld, H.; Lemlek, J.; Lee, J.; Iskandrian, B.; Heo, J. Differentiation between primary dilated cardiomyopathy and ischemic cardiomyopathy based on right ventricular performance. *Am. Heart J.* 1992, 123, 768–773. [CrossRef]

17. Wu, M.Y.; Yang, G.T.; Liao, W.T.; Tsai, A.P.Y.; Cheng, Y.L.; Cheng, P.W.; Li, C.Y.; Li, C.J. Current Mechanistic Concepts in Ischemia and Reperfusion Injury. *Cell. Physiol. Biochem.* 2018, 46, 1650–1667. [CrossRef]

18. Lipshultz, S.E.; Cochran, T.R.; Briston, D.A.; Brown, S.R.; Sambatakos, P.J.; Miller, T.L.; Carrillo, A.A.; Corcia, L.; Sanchez, J.E.; Diamond, M.B.; et al. Pediatric cardiomyopathies: Causes, epidemiology, clinical course, preventive strategies and therapies. *Future Cardiol.* 2013, 9, 817–848. [CrossRef]

19. Towbin, J.A.; Lowe, A.M.; Colan, S.D.; Sleeper, L.A.; Orav, E.J.; Clunie, S.; Messere, J.; Cox, G.F.; Lurie, P.R.; Hsu, D.; et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. *JAMA* 2006, 296, 1867–1876. [CrossRef]

20. Patel, M.D.; Mohan, J.; Schneider, C.; Bajpai, G.; Purevjav, E.; Canter, C.E.; Towbin, J.; Bredermeyer, A.; Lavine, K.J. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. *JCI Insight* 2017, 2, 94382. [CrossRef]

21. Song, W.; Shou, W. Cardiac sodium channel Nav1.5 mutations and cardiac arrhythmia. *Pediatr. Cardiol.* 2012, 33, 943–949. [CrossRef]

22. Messer, A.E.; Marston, S.B. Investigating the role of uncoupling of troponin I phosphorylation from changes in myofibrillar Ca2+-sensitivity in the pathogenesis of cardiomyopathy. *Front. Physiol.* 2014, 5, 315. [CrossRef]

23. Bai, F.; Wang, L.; Kawai, M. A study of tropomyosin’s role in cardiac function and disease using thin-filament reconstituted myocardium. *J. Muscle Res. Cell Motil.* 2013, 34, 295–310. [CrossRef]

24. Opie, L.H.; Commerford, P.; Gersh, B.J.; Pfeffer, M.A. Controversy in ventricular remodelling. *Lancet* 2006, 367, 356–367. [CrossRef]

25. Fatkin, D. Familial dilated cardiomyopathy: Current challenges and future directions. *Glob. Cardiol. Sci. Pract.* 2012, 8. [CrossRef]

26. Petretta, M.; Pirozzi, F.; Sasso, L.; Paglia, A.; Bonaduce, D. Review and metaanalysis of the frequency of familial dilated cardiomyopathy. *Am. J. Cardiol.* 2011, 108, 1171–1176. [CrossRef] [PubMed]

27. Ganesh Santhi, K.; Arnett Donna, K.; Assimes Themistocles, L.; Basson Craig, T.; Chakravarti, A.; Ellinor Patrick, T.; Engler Mary, B.; Goldmuntz, E.; Herrington David, M.; Hershberger Ray, E.; et al. Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update. *Circulation* 2013, 128, 2813–2851. [CrossRef]

28. Ware, J.S.; Cook, S.A. Role of titin in cardiomyopathy: From DNA variants to patient stratification. *Nat. Rev. Cardiol.* 2018, 15, 241–252. [CrossRef]

29. Linke, W.A. Sense and stretchability: The role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. *Cardiovasc. Res.* 2008, 77, 637–648. [CrossRef]

30. Gautel, M. The sarcomeric cytoskeleton: Who picks up the strain? *Curr. Opin. Cell Biol.* 2011, 23, 39–46. [CrossRef]

31. Linke, W.A.; Hamdani, N. Gigantic business: Titin properties and function through thick and thin. *Circ. Res.* 2014, 114, 1052–1068. [CrossRef]

32. Tskhovrebova, L.; Trinick, J. Roles of titin in the structure and elasticity of the sarcomere. *J. Biomed. Biotechnol.* 2010, 2010, 612482. [CrossRef] [PubMed]

33. Morimoto, S.; Lu, Q.W.; Harada, K.; Takahashi-Yanaga, F.; Minakami, R.; Ohta, M.; Sasaguri, T.; Ohtsuki, I. Ca2+-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T causes familial dilated cardiomyopathy. *Proc. Natl. Acad. Sci. USA* 2002, 99, 913–918. [CrossRef] [PubMed]

34. Liew, A.C.; Vassiliou, V.S.; Cooper, R.; Raphael, C.E. Hypertrophic Cardiomyopathy—Past, Present and Future. *J. Clin. Med.* 2017, 6, 118. [CrossRef]
35. Maron, B.J.; Ommen, S.R.; Semsarian, C.; Spirito, P.; Olivotto, I.; Maron, M.S. Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. *J. Am. Coll. Cardiol.* 2014, 64, 83–99. [CrossRef]

36. Gersh, B.J.; Maron, B.J.; Bonow, R.O.; Dearani, J.A.; Fifer, M.A.; Link, M.S.; Naidu, S.S.; Nishimura, R.A.; Ommen, S.R.; Rakowski, H.; et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011, 124, 2761–2796. [CrossRef]

37. Goyal, V.; Jassal, D.S.; Dhall, N.S. Pathophysiology and prevention of sudden cardiac death. *Can. J. Physiol. Pharmacol.* 2016, 94, 237–244. [CrossRef]

38. Yang, Q.; Sanbe, A.; Osinska, H.; Hewett, T.E.; Klevitsky, R.; Robbins, J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. *J. Clin. Invest.* 1998, 102, 1292–1300. [CrossRef]

39. Yang, Q.; Sanbe, A.; Osinska, H.; Hewett, T.E.; Klevitsky, R.; Robbins, J. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. *Circ. Res.* 1999, 85, 841–847. [CrossRef] [PubMed]

40. Manabe, S.; Kasegawa, H.; Arai, H.; Takanashi, S. Management of systolic anterior motion of the mitral valve: A mechanism-based approach. *Gen. Thorac. Cardiovasc. Surg.* 2018, 66, 379–389. [CrossRef] [PubMed]

41. MacIver, D.H.; Clark, A.L. Contractile Dysfunction in Sarcomeric Hypertrophic Cardiomyopathy. *J. Card. Fail.* 2016, 22, 731–737. [CrossRef]

42. Lee, S.R.; Han, J. Mitochondrial Mutations in Cardiac Disorders. *Adv. Exp. Med. Biol.* 2017, 982, 81–111.

43. Ren, X.; Hensley, N.; Brady, M.B.; Gao, W.D. The Genetic and Molecular Bases for Hypertrophic Cardiomyopathy: The Role for Calcium Sensitization. *J. Cardiothorac. Vasc. Anesth.* 2018, 32, 478–487. [CrossRef]

44. Soetkamp, D.; Raedschelders, K.; Mastali, M.; Sobhani, K.; Bairey Merz, C.N.; Van Eyk, J. The continuing evolution of cardiac troponin I biomarker analysis: From protein to proteoform. *Expert Rev. Proteomics* 2017, 14, 973–986. [CrossRef]

45. Zhuge, R.; Zhou, R.; Ni, X. Progress in Molecular Genetic Study of Mitochondrial Cardiomyopathy. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2017, 39, 438–444.

46. El-Hattab, A.W.; Dai, H.; Almannahi, M.; Wang, J.; Faqib, E.A.; Al Asmari, A.; Saleh, M.A.M.; Elamin, M.A.O.; Alfadhel, M.; Alkuraya, F.S.; et al. Molecular and clinical spectra of FBXL4 deficiency. *Hum. Mutat.* 2017, 38, 1649–1659. [CrossRef]

47. Coppini, R.; Ferrantini, C.; Poggesi, C.; Mugelli, A.; Olivotto, I. Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling. *Giornale Italiano di Cardiologia* 2016, 17, 189–196.

48. Landstrom, A.P.; Ackerman, M.J. Beyond the cardiac myofilament: Hypertrophic cardiomyopathy-associated mutations in genes that encode calcium-handling proteins. *Curr. Mol. Med.* 2012, 12, 507–518. [CrossRef]

49. Kensler, R.W.; Shafer, J.F.; Harris, S.P. Binding of the N-terminal fragment C0-C2 of cardiac MyBP-C to cardiac F-actin. *J. Struct. Biol.* 2011, 174, 44–51. [CrossRef]

50. McNally, E.M.; Barefield, D.Y.; Puckelwartz, M.J. The genetic landscape of cardiomyopathy and its role in heart failure. *Cell Metab.* 2015, 21, 174–182. [CrossRef]

51. Moore, J.R.; Leinwand, L.; Warshaw, D.M. Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. *Circ. Res.* 2012, 111, 375–385. [CrossRef]

52. Walsh, R.; Rutland, C.; Thomas, R.; Loughna, S. Cardiomyopathy: A systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations. *Cardiology* 2010, 115, 49–60. [CrossRef]

53. Kittleson, M.D.; Meurs, K.M.; Munro, M.J.; Kittleson, J.A.; Liu, S.K.; Pion, P.D.; Towbin, J.A. Familial hypertrophic cardiomyopathy in maine coon cats: An animal model of human disease. *Circulation* 1999, 99, 3172–3180. [CrossRef]

54. Marian, A.J.; Wu, Y.; Lim, D.S.; McCluggage, M.; Youker, K.; Yu, Q.T.; Brugada, R.; DeMayo, F.; Quinones, M.; Roberts, R. A transgenic rabbit model for human hypertrophic cardiomyopathy. *J. Clin. Investig.* 1999, 104, 1683–1692. [CrossRef]

55. Niimura, H.; Bachinski, L.L.; Sangwatanaroj, S.; Watkins, H.; Chudley, A.E.; McKenna, W.; Kristinsson, A.; Roberts, R.; Sole, M.; Maron, B.J.; et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. *N. Engl. J. Med.* 1998, 338, 1248–1257. [CrossRef]
56. Bonne, G.; Carrier, L.; Bercovici, J.; Cruaud, C.; Richard, P.; Hainque, B.; Gautel, M.; Labeit, S.; James, M.; Beckmann, J.; et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat. Genet. 1995, 11, 438–440. [CrossRef]

57. Van Dijk, S.J.; Dooijes, D.; dos Remedios, C.; Michels, M.; Lamers, J.M.; Winegrad, S.; Schlossarek, S.; Carrier, L; ten Cat, F.J.; Stienen, G.J.; et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: Haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009, 119, 1473–1483. [CrossRef]

58. Freiburg, A.; Gautel, M. A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric in familial hypertrophic cardiomyopathy. Eur. J. Biochem. 1996, 235, 317–323. [CrossRef]

59. Gilbert, R.; Kelly, M.G.; Mikawa, T.; Fushman, D.A. The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J. Cell Sci. 1996, 109 Pt 1, 101–111.

60. Barefield, D.; Sadayappan, S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J. Mol. Cell. Cardiol. 2008, 40, 866–875. [CrossRef] [PubMed]

61. Bezdold, K.L.; Shaffer, J.F.; Khosa, J.K.; Hoye, E.R.; Harris, S.P. A gain-of-function mutation in the M-domain of cardiac myosin-binding protein-C increases binding to actin. J. Biol. Chem. 2013, 288, 21496–21505. [CrossRef]

62. Kunst, G.; Kress, K.R.; Gruen, M.; Uttenweiler, D.; Gautel, M.; Fink, R.H. Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. Circ. Res. 2000, 86, 51–58. [CrossRef] [PubMed]

63. Sadayappan, S.; Gulick, J.; Osinska, H.; Martin, L.A.; Hahn, H.S.; Dorn, G.W., 2nd; Kleivitsky, R.; Seidman, C.E.; Seidman, J.G.; Robbins, J. Cardiac myosin binding protein-C phosphorylation and cardiac function. Circ. Res. 2005, 97, 1156–1163. [CrossRef] [PubMed]

64. Sadayappan, S.; Osinska, H.; Kleivitsky, R.; Lorenz, J.N.; Sargent, M.; Molkentin, J.D.; Seidman, C.E.; Seidman, J.G.; Robbins, J. Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc. Natl. Acad. Sci. USA 2006, 103, 16918–16923. [CrossRef]

65. Morner, S.; Richard, P.; Kazzam, E.; Hellman, U.; Hainque, B.; Schwartz, K.; Waldenstrom, A. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. J. Mol. Cell. Cardiol. 2003, 35, 841–849. [CrossRef]

66. Erdmann, J.; Daenhlow, S.; Wischke, S.; Senyuva, M.; Werner, U.; Raible, J.; Tanis, N.; Dyachenko, S.; Hummel, M.; Hetzer, R.; et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin. Genet. 2003, 64, 339–349. [CrossRef] [PubMed]

67. Van Driest, S.L.; Ommen, S.R.; Tajik, A.J.; Gersh, B.J.; Ackerman, M.J. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin. Proc. 2005, 80, 739–744. [CrossRef]

68. Richard, P.; Charron, P.; Carrier, L.; Ledeuil, C.; Cheav, T.; Pichereau, C.; Benaiche, A.; Isnard, R.; Dubourg, O.; Burban, M.; et al. Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003, 107, 2227–2232. [CrossRef] [PubMed]

69. Parvatiyar, M.S.; Ommen, S.R.; Figueiredo-Freitas, C.; Potter, J.D.; Ackerman, M.J.; Pinto, J.R. A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation. J. Biol. Chem. 2012, 287, 31845–31855. [CrossRef]

70. Landstrom, A.P.; Adekola, B.A.; Bos, J.M.; Ommen, S.R.; Ackerman, M.J. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: Summary of the literature and implications for genetic testing. Am. Heart J. 2011, 161, 165–171. [CrossRef]

71. Landstrom, A.P.; Weisleder, N.; Batalden, K.B.; Bos, J.M.; Tester, D.J.; Ommen, S.R.; Wehrens, X.H.; Claycomb, W.C.; Ko, J.K.; Hwang, M.; et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J. Mol. Cell. Cardiol. 2007, 42, 1026–1035. [CrossRef] [PubMed]

72. Fujino, N.; Ino, H.; Hayashi, K.; Uchiyama, K.; Nagata, M.; Konno, T.; Katoh, H.; Sakamoto, Y.; Tsukubawa, T.; Ohsato, K.; et al. Abstract 915: A Novel Missense Mutation in Cardiac Ryanodine Receptor Gene as a Possible Cause of Hypertrophic Cardiomyopathy: Evidence From Familial Analysis. Circulation 2006, 114, II_165.

73. Maron Martin, S.; Olivotto, I.; Zenovich Andrey, G.; Link Mark, S.; Pandian Natesa, G.; Kuvim Jeffery, T.; Nistri, S.; Cecchi, E.; Udelson James, E.; Maron Barry, J. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. Circulation 2006, 114, 2232–2239. [CrossRef]
74. Dimitrov, P.P.; Rajtar-Salwa, R. Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment. *Biomed Res. Int.* 2016, 2016, 1575130. [CrossRef] [PubMed]

75. Seferovic, P.M.; Paulus, W.J. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. *Eur. Heart J.* 2015, 36, 1718–1727. [CrossRef]

76. Brown, K.N.; Diaz, R.R. Restrictive (Infiltrative) Cardiomyopathy. In *StatPearls*; StatPearls Publishing LLC.: Treasure Island, FL, USA, 2018.

77. Kostareva, A.; Kiselev, A.; Gudkova, A.; Frishman, G.; Ruepp, A.; Frishman, D.; Smolina, N.; Tarnovskaya, S.; Nilsson, D.; Zlotina, A.; et al. Genetic Spectrum of Idiopathic Restrictive Cardiomyopathy Uncovered by Next-Generation Sequencing. *PLoS ONE* 2016, 11, e0163362. [CrossRef] [PubMed]

78. Parvatiyar, M.S.; Pinto, J.R.; Dweck, D.; Potter, J.D. Cardiac troponin mutations and restrictive cardiomyopathy. *J. Biomed. Biotechnol.* 2010, 2010, 350706. [CrossRef]

79. Gordon, A.M.; Homsher, E.; Regnier, M. Regulation of contraction in striated muscle. *Physiol. Rev.* 2000, 80, 853–924. [CrossRef]

80. Gordon, A.M.; Regnier, M.; Homsher, E. Skeletal and cardiac muscle contractile activation: Tropomyosin “rocks and rolls”. *News Physiol. Sci.* 2001, 16, 49–55. [CrossRef]

81. Kobayashi, T.; Solaro, R.J. Increased Ca\textsuperscript{2+} affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I. *J. Biol. Chem.* 2006, 281, 13471–13477. [CrossRef] [PubMed]

82. Gomes, A.V.; Liang, J.; Potter, J.D. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. *J. Biol. Chem.* 2005, 280, 30909–30915. [CrossRef]

83. Kaski, J.P.; Syrris, P.; Burch, M.; Tome-Esteban, M.T.; Fenton, M.; Christiansen, M.; Andersen, P.S.; Sebire, N.; Ashworth, M.; Deanfield, J.E.; et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. *Heart* 2008, 94, 1478–1484. [CrossRef]

84. Sweet, M.; Taylor, M.R.; Mestroni, L. Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. *Expert Opin. Orphan Drugs* 2015, 3, 869–876. [CrossRef] [PubMed]

85. Husser, D.; Ueberham, L.; Jacob, J.; Heuer, D.; Riedel-Heller, S.; Walker, J.; Hindricks, G.; Bollmann, A. Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients. *PLoS ONE* 2018, 13, e0196612. [CrossRef] [PubMed]

86. Pereira, N.L.; Grogan, M.; Dec, G.W. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series. *J. Am. Coll. Cardiol.* 2018, 71, 1130–1148. [CrossRef]

87. Pereira, N.L.; Grogan, M.; Dec, G.W. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 2 of a 2-Part Series. *J. Am. Coll. Cardiol.* 2018, 71, 1149–1166. [CrossRef]

88. Yadav, S.; Sitbon, Y.H.; Kazmierczak, K.; Szczesna-Cordary, D. Hereditary heart disease: Pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains. *Pflug. Arch.* 2019. [CrossRef]

89. Rammos, A.; Meladinis, V.; Vovas, G.; Fatouros, D. Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment-A Systematic Review. *Radiol. Res. Pract.* 2017, 2017, 2874902. [CrossRef]

90. Mogensen, J.; Kubo, T.; Duque, M.; Uribe, W.; Shaw, A.; Murphy, R.; Gimeno, J.R.; Elliott, P.; McKenna, W.J. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. *J. Clin. Investig.* 2003, 111, 209–216. [CrossRef]

91. Gemayel, C.; Pelliccia, A.; Thompson, P.D. Arrhythmogenic right ventricular cardiomyopathy. *J. Am. Coll. Cardiol.* 2001, 38, 1773–1781. [CrossRef]

92. Ohno, S. The genetic background of arrhythmogenic right ventricular cardiomyopathy. *J. Arrhythmia* 2016, 32, 398–403. [CrossRef]

93. Norgett, E.E.; Hatsell, S.J.; Carvajal-Huerta, L.; Cabezás, J.C.; Common, J.; Purkis, P.E.; Whittlock, N.; Leigh, I.M.; Stevens, H.P.; Kelsell, D.P. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. *Hum. Mol. Genet.* 2000, 9, 2761–2766. [CrossRef]
94. McKoy, G.; Protonotarios, N.; Crosby, A.; Tsatsopoulou, A.; Anastakis, A.; Coonar, A.; Norman, M.; Baboonian, C.; Jeffery, S.; McKenna, W.J. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000, 355, 2119–2124. [CrossRef]

95. Marcus, F.I.; Edson, S.; Towbin, J.A. Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy: A Practical Guide for Physicians. J. Am. Coll. Cardiol. 2013, 61, 1945–1948. [CrossRef]

96. James, C.A.; Bhonsale, A.; Tichnell, C.; Murray, B.; Russell, S.D.; Tandri, H.; Tedford, R.J.; Judge, D.P.; Calkins, H. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J. Am. Coll. Cardiol. 2013, 62, 1290–1297. [CrossRef]

97. Dalal, D.; James, C.; Devanagondi, R.; Tichnell, C.; Tucker, A.; Prakasa, K.; Spevak, P.J.; Bluemke, D.A.; Abraham, T.; Russell, S.D.; et al. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48, 1416–1424. [CrossRef]

98. Kirchhof, P.; Fabritz, L.; Zwiener, M.; Witt, H.; Schafers, M.; Zellerhoff, S.; Paul, M.; Athai, T.; Hiller, K.H.; Baba, H.A.; et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 2006, 114, 1799–1806. [CrossRef]

99. Que, D.; Yang, P.; Song, X.; Liu, L. Traditional vs. genetic pathogenesis of arrhythmogenic right ventricular cardiomyopathy. Europace 2015, 17, 1770–1776. [CrossRef]

100. Roux-Buisson, N.; Gandjimbakhch, E.; Donal, E.; Probst, V.; Chevalier, P.; Klug, D.; Mansencal, N.; Delacretaz, E.; Cosnay, P.; et al. Prevalence and significance of rare RYR2 variants in arrhythmogenic right ventricular cardiomyopathy/dysplasia: Results of a systematic screening. Heart Rhythm 2014, 11, 1999–2009. [CrossRef]

101. Coonar, A.S.; Protonotarios, N.; Tsatsopoulou, A.; Needham, E.W.; Houlston, R.S.; Cliff, S.; Otter, M.I.; Murday, V.A.; Mattu, R.K.; McKenna, W.J. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonpidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation 1998, 97, 2049–2058. [CrossRef]

102. Rampazzo, A.; Nava, A.; Danieli, G.A.; Buja, G.; Daliento, L.; Fasoli, G.; Scognamiglio, R.; Corrado, D.; Thiene, G. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum. Mol. Genet. 1994, 3, 959–962. [CrossRef]

103. Rampazzo, A.; Nava, A.; Malacrida, S.; Belfagna, G.; Bauce, B.; Rossi, V.; Zimbello, R.; Simionati, B.; Basso, C.; Thiene, G.; et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am. J. Hum. Genet. 2002, 71, 1200–1206. [CrossRef]

104. Garcia-Gras, E.; Lombardi, R.; Giocondo, M.J.; Willerson, J.T.; Schneider, M.D.; Khoury, D.S.; Mariani, A.J. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J. Clin. Invest. 2006, 116, 2012–2021. [CrossRef]

105. Hulot, J.S.; Jouven, X.; Empana, J.P.; Frank, R.; Fontaine, G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2004, 110, 1879–1884. [CrossRef] [PubMed]

106. Dalal, D.; Nasir, K.; Bomma, C.; Prakasa, K.; Tandri, H.; Piccini, J.; Roguin, A.; Tichnell, C.; James, C.; Russell, S.D.; et al. Arrhythmogenic right ventricular dysplasia: A United States experience. Circulation 2005, 112, 3823–3832. [CrossRef] [PubMed]

107. Elliott, P.; Andersson, B.; Arbustini, E.; Bilinska, Z.; Cecchi, F.; Charron, P.; Dubourg, O.; Kuhl, U.; Maisch, B.; McKenna, W.J.; et al. Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2008, 29, 270–276. [CrossRef]

108. Towbin, J.A.; Lorts, A.; Jefferies, J.L. Left ventricular non-compaction cardiomyopathy. Lancet 2015, 386, 813–825. [CrossRef]

109. Henderson, D.J.; Anderson, R.H. The development and structure of the ventricles in the human heart. Pediatr. Cardiol. 2009, 30, 588–596. [CrossRef] [PubMed]

110. Ichida, F.; Tsubata, S.; Bowles, K.R.; Haneda, N.; Uese, K.; Miyawaki, T.; Dreyer, W.J.; Messina, J.; Li, H.; Bowles, N.E.; et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 2001, 103, 1256–1263. [CrossRef]
130. Riabowol, K.T.; Vosatka, R.J.; Ziff, E.B.; Lamb, N.J.; Feramisco, J.R. Microinjection of fos-specific antibodies blocks DNA synthesis in fibroblast cells. *Mol. Cell. Biol.* **1988**, *8*, 1670–1676. [CrossRef] [PubMed]

131. Hunter, J.J.; Chien, K.R. Signaling Pathways for Cardiac Hypertrophy and Failure. *N. Engl. J. Med.* **1999**, *341*, 1276–1283. [CrossRef]

132. Lázár-Molnár, E.; Hegyesi, H.; Tóth, S.; Falus, A. Autocrine And Paracrine Regulation By Cytokines And Growth Factors In Melanoma. *Cytokine* **2000**, *12*, 547–554. [CrossRef]

133. Brand, T.; Schneider, M.D. The TGF beta superfamily in myocardium: Ligands, receptors, transduction, and function. *J. Mol. Cell. Cardiol.* **1995**, *27*, 5–18. [CrossRef]

134. Hefti, M.A.; Harder, B.A.; Eppenberger, H.M.; Schaub, M.C. Signaling pathways in cardiac myocyte hypertrophy. *J. Mol. Cell. Cardiol.* **1997**, *29*, 2873–2892. [CrossRef] [PubMed]

135. Gelb, B.D.; Cavé, H.; Dillon, M.W.; Gripp, K.W.; Lee, J.A.; Mason-Suares, H.; Rauen, K.A.; Williams, B.; Zenker, M.; Vincent, L.M.; et al. ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation. *Genet. Med.* **2018**, *20*, 1334–1345. [CrossRef]

136. Dhandapany, P.S.; Razzaque, M.A.; Muthusami, U.; Kunnoth, S.; Edwards, J.J.; Mulero-Navarro, S.; Riess, I.; Pardo, S.; Sheng, J.; Rani, D.S.; et al. RAF1 mutations in childhood-onset dilated cardiomyopathy. *Nat. Genet.* **2014**, *46*, 635–639. [CrossRef] [PubMed]

137. Gelb, B.D.; Tartaglia, M. RAS signaling pathway mutations and hypertrophic cardiomyopathy: Getting into and out of the thick of it. *J. Clin. Invest.* **2011**, *121*, 844–847. [CrossRef]

138. Pandit, B.; Sarkozy, A.; Pennacchio, L.A.; Carta, C.; Oishi, K.; Martinelli, S.; Pogna, E.A.; Schackwitz, W.; Ustaszewska, A.; Landstrom, A.; et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. *Nat. Genet.* **2007**, *39*, 1007–1012. [CrossRef] [PubMed]

139. Neves, S.R.; Ram, P.T.; Iyengar, R. G protein pathways. *Science* **2002**, *296*, 1636–1639. [CrossRef]

140. Rockman, H.A.; Koch, W.J.; Lefkowitz, R.J. Seven-transmembrane-spanning receptors and heart function. *Nature* **2002**, *415*, 206–212. [CrossRef]

141. Hamm, H.E. The many faces of G protein signaling. *J. Biol. Chem.* **1998**, *273*, 669–672. [CrossRef]

142. Bernardo, B.C.; Weeks, K.L.; Pretorius, L.; McMullen, J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. *Pharmacol. Ther.* **2010**, *128*, 191–227. [CrossRef]

143. Srniskova, M.; Barancik, M.; Neckar, J.; Ravingerova, T. Mitogen-activated protein kinases in the acute diabetic myocardium. *Mol. Cell. Biochem.* **2003**, *249*, 59–65. [CrossRef] [PubMed]

144. Tan, Y.; Ichikawa, T.; Li, J.; Si, Q.; Yang, H.; Chen, X.; Goldblatt, C.S.; Meyer, C.J.; Li, X.; Cai, L.; et al. Diabetic Downregulation of Nrf2 Activity via ERK Contributes to Oxidative Stress–Induced Insulin Resistance in Cardiac Cells In Vitro and In Vivo. *Diabetes* **2011**, *60*, 625–633. [CrossRef] [PubMed]

145. Obermann, W.M.; Gautel, M.; Steiner, F.; van der Ven, P.F.; Weber, K.; Forst, D.O. The structure of the sarcomeric M band: Localization of defined domains of myomesin, M-protein, and the 250-kD carboxy-terminal region of titin by immunoelectron microscopy. *Cell Biol.* **1996**, *134*, 1441–1453. [CrossRef] [PubMed]

146. Gautel, M. Cytoskeletal protein kinases: Titin and its relations in mechanosensing. *J. Biol. Chem.* **1998**, *273*, 1441–1453. [CrossRef] [PubMed]

147. Lange, S.; Xiang, F.; Yakovenko, A.; Vihola, A.; Hackman, P.; Rostkova, E.; Kristensen, J.; Brandmeier, B.; Franzen, G.; Hedberg, B.; et al. The kinase domain of titin controls muscle gene expression and protein turnover. *Science* **2005**, *308*, 1599–1603. [CrossRef]

148. Bogomolovas, J.; Gasch, A.; Simkovic, F.; Rigden, D.J.; Labeit, S.; Mayans, O. Titin kinase is an inactive pseudokinase scaffold that supports MuRF1 recruitment to the sarcomeric M-line. *Open Biol.* **2014**, *4*, 140041. [CrossRef]

149. Arber, S.; Hunter, J.J.; Ross, J., Jr.; Hong, M.; Sansig, G.; Borg, J.; Perriard, J.C.; Chien, K.R.; Caroni, P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. *Cell* **1997**, *88*, 393–403. [CrossRef]

150. Knoll, R.; Hoshiba, M.; Hoffman, H.M.; Person, V.; Lorenzen-Schmidt, I.; Bang, M.L.; Hayashi, T.; Shiga, N.; Yasukawa, H.; Schaper, W.; et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. *Cell* **2002**, *111*, 943–955. [CrossRef]
152. Knoll, R.; Kostin, S.; Klude, S.; Savvatis, K.; Klinge, L.; Stehle, J.; Gunke, S.; Kotter, S.; Babicz, K.; Sohns, M.; et al. A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. Circ. Res. 2010, 106, 695–704. [CrossRef]

153. Witt, C.C.; Witt, S.H.; Lerche, S.; Labeit, D.; Back, W.; Labeit, S. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. EMBO J. 2008, 27, 350–360. [CrossRef]

154. Witt, C.C.; Witt, S.H.; Lerche, S.; Labeit, D.; Back, W.; Labeit, S. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. EMBO J. 2008, 27, 350–360. [CrossRef]

155. Markowska, A.; Pawałowska, M.; Lubin, J.; Markowska, J. Signalling pathways in endometrial cancer. Curr. Pharm. Des. 2011, 17, 3837–3847. [CrossRef] [PubMed]

156. Yang, C.-Y.; Chen, C.-S.; Yiang, G.-T.; Cheng, Y.-L.; Yong, S.-B.; Wu, M.-Y.; Li, C.-J. New Insights into the molecular mechanisms underlying breast cancer progression. Breast Cancer Res. Treat. 2014, 144, 815–825. [CrossRef] [PubMed]

157. Aoyagi, T.; Matsui, T. Phosphoinositide-3-kinase signaling in cardiac hypertrophy and heart failure. Curr. Pharm. Des. 2011, 17, 1818–1824. [CrossRef] [PubMed]

158. Hagiwara, A.; Cornu, M.; Cybulski, N.; Polak, P.; Betz, C.; Trapani, F.; Terracciano, L.; Heim, M.H.; Ruegg, M.A.; Hall, M.N. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 2012, 15, 725–738. [CrossRef] [PubMed]

159. Shiojima, I.; Sato, K.; Izumiya, Y.; Schiekofer, S.; Ito, M.; Liao, R.; Colucci, W.S.; Walsh, K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Investig. 2005, 115, 2108–2118. [CrossRef] [PubMed]

160. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M.M.; Simons, J.W.; Semenza, G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60, 1541–1545. [CrossRef] [PubMed]

161. Hudson, C.C.; Liu, M.; Chiang, G.G.; Otterness, D.M.; Loomis, D.C.; Kaper, F.; Giaccia, A.J.; Abraham, R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2006, 26, 3345–3356. [CrossRef] [PubMed]

162. Shiojima, I.; Sato, K.; Izumiya, Y.; Schiekofer, S.; Ito, M.; Liao, R.; Colucci, W.S.; Walsh, K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Investig. 2005, 115, 2108–2118. [CrossRef] [PubMed]

163. Michael, A.; Haq, S.; Chen, X.; Hsieh, E.; Cui, L.; Walters, B.; Shao, Z.; Bhattacharya, K.; Kilter, H.; Huggins, G.; et al. Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J. Biol. Chem. 2004, 279, 21383–21393. [CrossRef] [PubMed]

164. Lal, H.; Ahmad, F.; Woodgett, J.; Force, T. The GSK-3 family as therapeutic target for myocardial diseases. Circ. Res. 2015, 116, 138–149. [CrossRef]

165. Cheng, H.; Woodgett, J.; Maamari, M.; Force, T. Targeting GSK-3 family members in the heart: A very sharp double-edged sword. J. Mol. Cell. Cardiol. 2011, 51, 607–613. [CrossRef] [PubMed]

166. Stauffer, B.L.; Konhilas, J.P.; Luczak, E.D.; Leinwand, L.A. Soy diet worsens heart disease in mice. J. Clin. Investig. 2006, 116, 209–216. [CrossRef] [PubMed]

167. Luckey, S.W.; Walker, L.A.; Smyth, T.; Mansoori, J.; Messmer-Kratzsch, A.; Rosenzweig, A.; Olson, E.N.; Leinwand, L.A. The role of Akt/GSK-3beta signaling in familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 2009, 46, 739–747. [CrossRef]

168. Narula, J.; Kolodgie, F.D.; Virmani, R. Apoptosis and cardiomyopathy. Curr. Opin. Cardiol. 2000, 15, 183–188. [CrossRef] [PubMed]

169. Hong, B.K.; Kwon, H.M.; Byun, K.H.; Kim, D.; Choi, E.Y.; Kang, T.S.; Kang, S.M.; Chun, K.J.; Jung, Y.; Kim, H.S.; et al. Apoptosis in dilated cardiomyopathy. Korean J. Intern. Med. 2000, 15, 56–64. [CrossRef] [PubMed]

170. Schaper, J.; Lorenz-Meyer, S.; Suzuki, K. The role of apoptosis in dilated cardiomyopathy. Herz 1999, 24, 219–224. [CrossRef] [PubMed]

171. Communal, C.; Singh, K.; Pimentel, D.R.; Colucci, W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998, 88, 1329–1334. [CrossRef] [PubMed]
172. Geng, Y.-J.; Ishikawa, Y.; Vatner Dorothy, E.; Wagner Thomas, E.; Bishop Sanford, P.; Vatner Stephen, F.; Homcy Charles, J. Apoptosis of Cardiac Myocytes in Gsa Transgenic Mice. Circ. Res. 1999, 84, 34–42. [CrossRef]

173. Iwai-Kanai, E.; Hasegawa, K.; Araki, M.; Kakita, T.; Morimoto, T.; Sasayama, S. α- and β-Adrenergic Pathways Differentially Regulate Cell Type–Specific Apoptosis in Rat Cardiac Myocytes. Circulation 1999, 100, 305–311. [CrossRef]

174. Teiger, E.; Than, V.D.; Richard, L.; Wisnewsky, C.; Tea, B.S.; Gaboury, L.; Tremblay, J.; Schwartz, K.; Hamet, P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J. Clin. Investig. 1996, 97, 2891–2897. [CrossRef] [PubMed]

175. Narula, N.; Zaragoza, M.V.; Sengupta, P.P.; Li, P.; Haider, N.; Verjans, J.; Waymire, K.; Vannan, M.; Wallace, D.C. Adenine nucleotide translocase 1 deficiency results in dilated cardiomyopathy with defects in myocardial mechanics, histopathological alterations, and activation of apoptosis. JACC Cardiovasc. Imaging 2011, 4, 1–10. [CrossRef] [PubMed]

176. El-Hattab, A.W.; Scaglia, F. Mitochondrial Cardiomyopathies. Front. Cardiovasc. Med. 2016, 3, 25. [CrossRef] [PubMed]

177. Machackova, J.; Barta, J.; Dhalla, N.S. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies. Can. J. Cardiol. 2006, 22, 953–968. [CrossRef]

178. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [CrossRef]

179. Görtl, B.; Kratky, D.; Guelly, C.; Zhang, L.; Gorkiewicz, G.; Das, S.K.; Tamilarasan, K.P.; Hoefler, G. Apoptosis and fibrosis are early features of heart failure in an animal model of metabolic cardiomyopathy. Int. J. Exp. Pathol. 2009, 90, 338–346. [CrossRef] [PubMed]

180. Narula, J.; Haider, N.; Virmani, R.; DiSalvo, T.G.; Kolodgie, F.D.; Hajjar, R.J.; Schmidt, U.; Semigran, M.J.; Dec, G.W.; Khaw, B.A. Apoptosis in myocytes in end-stage heart failure. N. Engl. J. Med. 1996, 335, 1182–1189. [CrossRef]

181. Olivetti, G.; Abbi, R.; Quaini, F.; Kajstura, J.; Cheng, W.; Nitahara, J.A.; Quaini, E.; Di Loreto, C.; Beltrami, C.A.; Krajewski, S.; et al. Apoptosis in the failing human heart. N. Engl. J. Med. 1997, 336, 1131–1141. [CrossRef]

182. Krown, K.A.; Page, M.T.; Nguyen, C.; Zechner, D.; Gutierrez, V.; Comstock, K.L.; Glembocki, C.C.; Quintana, P.J.; Sabbadini, R.A. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Investig. 1996, 98, 2854–2865. [CrossRef]

183. Torre-Amione, G.; Kapadia, S.; Lee, J.; Durand, J.B.; Bies, R.D.; Young, J.B.; Mann, D.L. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93, 704–711. [CrossRef] [PubMed]

184. Akyurek, O.; Akyurek, N.; Sayin, T.; Dincer, I.; Berkalp, B.; Akyol, G.; Ozenci, M.; Oral, D. Association between the severity of heart failure and the susceptibility of myocytes to apoptosis in patients with idiopathic dilated cardiomyopathy. Int. J. Cardiol. 2001, 80, 29–36. [CrossRef]

185. Gonzalez, A.; Fortuno, M.A.; Querejeta, R.; Ravassa, S.; Lopez, B.; Lopez, N.; Diez, J. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc. Res. 2003, 59, 549–562. [CrossRef]

186. Agrotis, A.; Kalinina, N.; Bobik, A. Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr. Vasc. Pharmacol. 2005, 3, 55–61. [CrossRef]

187. Dobaczewski, M.; Chen, W.; Frangogiannis, N.G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J. Mol. Cell. Cardiol. 2011, 51, 600–606. [CrossRef]

188. Khan, R.; Sheppard, R. Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006, 118, 10–24. [CrossRef]

189. Sanderson, J.E.; Lai, K.B.; Shum, I.O.; Wei, S.; Chow, L.T. Transforming growth factor-beta(1) expression in cardiomyopathy, valvular disease and arrhythmia. Immunology 2005, 116, 2891–2897. [CrossRef] [PubMed]

190. Li, G.; Borger, M.A.; Williams, W.G.; Weisel, R.D.; Mickel, D.A.G.; Wigle, E.D.; Li, R.-K. Regional overexpression of insulin-like growth factor-I and transforming growth factor-β1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2002, 123, 89–95. [CrossRef] [PubMed]

191. Bujak, M.; Frangogiannis, N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74, 184–195. [CrossRef]
192. Lijnen, P.J.; Petrov, V.V.; Fagard, R.H. Induction of cardiac fibrosis by transforming growth factor-beta(1). *Mol. Genet. Metab.* **2000**, *71*, 418–435. [CrossRef]

193. Courcelles, M.; Fremin, C.; Voisin, L.; Lemieux, S.; Meloche, S.; Thibault, P. Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions. *Mol. Syst. Biol.* **2013**, *9*, 669. [CrossRef] [PubMed]

194. Olivetti, G.; Melissari, M.; Balbi, T.; Quaini, F.; Cigola, E.; Sonnenblick, E.H.; Anversa, P. Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. *Cardiovasc. Res.* **1994**, *28*, 1199–1208. [CrossRef] [PubMed]

195. Anversa, P.; Kajstura, J.; Olivetti, G. Myocyte death in heart failure. *Curr. Opin. Cardiol.* **1996**, *11*, 245–251. [CrossRef] [PubMed]

196. Khan, S.; Joyce, J.; Margulies, K.B.; Tsuda, T. Enhanced Bioactive Myocardial Transforming Growth Factor-β in Advanced Human Heart Failure. *Circ. J.* **2014**, *78*, 2711–2718. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).